Market open

Eton Pharmaceuticals/$ETON

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Ticker

$ETON
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Deer Park, United States

Employees

30
Website
www.etonpharma.com

ETON Metrics

BasicAdvanced
$347M
-
-$0.21
1.26
-

$347M

1.26

$15.00

$3.03

225K

1.507

1.31

0.788

27.07

-5.63%

-9.68%

-33.35%

9.983

21.7

34.24

-645.875

5.64%

-343.28%

29.90%

-21.01%

What the Analysts think about ETON

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.

ETON Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ETON Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ETON News

AllArticlesVideos
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

GlobeNewsWire·2 weeks ago
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

GlobeNewsWire·4 weeks ago
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ETON

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eton Pharmaceuticals stock?

Eton Pharmaceuticals (ETON) has a market cap of $347M as of January 15, 2025.

What is the P/E ratio for Eton Pharmaceuticals stock?

The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of January 15, 2025.

Does Eton Pharmaceuticals stock pay dividends?

No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Eton Pharmaceuticals dividend payment date?

Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.

What is the beta indicator for Eton Pharmaceuticals?

Eton Pharmaceuticals (ETON) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.